Raid Aljumaily to Humans
This is a "connection" page, showing publications Raid Aljumaily has written about Humans.
Connection Strength
0.308
-
Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer. Pancreas. 2020 10; 49(9):e95-e96.
Score: 0.041
-
Spontaneous Regression of Metastatic Pancreatic Cancer: A Role for Recurrent Inflammation. Pancreas. 2019 01; 48(1):e4-e6.
Score: 0.037
-
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study. Am J Ther. 2018 Nov/Dec; 25(6):e767-e768.
Score: 0.036
-
Optimal management of bone metastases in prostate cancer. Curr Oncol Rep. 2011 Jun; 13(3):222-30.
Score: 0.022
-
Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma. Transpl Immunol. 2022 04; 71:101544.
Score: 0.011
-
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 09; 16(5):569-589.
Score: 0.011
-
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
Score: 0.011
-
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 2021 05; 155:151-155.
Score: 0.011
-
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Cancer Chemother Pharmacol. 2021 05; 87(5):689-700.
Score: 0.011
-
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2021 01 15; 27(2):447-459.
Score: 0.010
-
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Adv Ther. 2021 01; 38(1):350-365.
Score: 0.010
-
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020 10; 8(2).
Score: 0.010
-
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192.
Score: 0.010
-
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors. Clin Cancer Res. 2020 12 01; 26(23):6196-6203.
Score: 0.010
-
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
Score: 0.010
-
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555.
Score: 0.010
-
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019 01; 25(1):141-151.
Score: 0.009
-
Harnessing the PD-1 Pathway in Myelodysplastic Syndrome. Am J Ther. 2018 Nov/Dec; 25(6):e711-e712.
Score: 0.009
-
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019 06; 37(3):461-472.
Score: 0.009
-
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018 01; 19(1):51-64.
Score: 0.008
-
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer. Lung Cancer. 2014 Jan; 83(1):67-72.
Score: 0.006
-
Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res. 2013 Apr 15; 73(8):2457-2467.
Score: 0.006